Related Experiment Video
Updated: Jun 12, 2026
15:04
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Ivermectin interacts with human ABCG2
Márton Jani1, Ildikó Makai, Emese Kis
1Solvo Biotechnology, Budaörs, Hungary.
Journal of Pharmaceutical Sciences
|June 25, 2010
Summary
Ivermectin interacts strongly with human ABCG2 transporter, potentially impacting drug safety. This finding is crucial for understanding ivermectin
Area of Science:
- Pharmacology
- Biochemistry
- Drug Metabolism
Background:
- Ivermectin, an antiparasitic drug, has limited brain penetration due to ABCB1 transporter activity.
- ABCG2/Abcg2 is a key transporter at pharmacological barriers, but its interaction with ivermectin is complex and species-specific.
- Previous studies on ivermectin and Abcg2 were complicated by the influence of ABCB1/Abcb1.
Discussion:
- This study investigates the specific interaction between ivermectin and the human ABCG2 transporter.
- Utilizing cellular and membrane assays, we quantified the affinity of ivermectin for human ABCG2.
- The research addresses the confounding effects of ABCB1/Abcb1 observed in prior investigations.
Key Insights:
- Ivermectin exhibits a high-affinity interaction with the human ABCG2 transporter.
- The determined IC(50) values for this interaction range from 1 to 1.5 µM.
- This high-affinity binding suggests a significant role for ABCG2 in ivermectin's disposition.
Outlook:
- The identified interaction between ivermectin and human ABCG2 has implications for predicting drug-drug interactions.
- Further research is warranted to elucidate the clinical significance of this interaction.
- Understanding ABCG2's role can inform the safe use of ivermectin and co-administered medications.
Related Concept Videos
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...